Starling Oncology (NASDAQ: STLN) reported third-quarter 2026 revenue of $169.8 million and updated its full-year financial guidance. Revenue rose 24.3% year over year, while gross profit increased 62.1% to $30.7 million. Net loss narrowed to $15.748 million from $16.504 million. Adjusted EBITDA, a non-GAAP earnings measure, turned positive at $3.394 million versus negative $3.459 million.
Full-year revenue guidance narrowed to $650–$660 million from $650–$670 million; free cash flow guidance narrowed to $5–$10 million from $5–$15 million. Gross profit guidance is now $107–$110 million, and adjusted EBITDA guidance is $4–$6 million. The company expects fourth-quarter adjusted EBITDA of $3–$5 million. Specialty pharmacy revenue grew 44% to $109 million. The medical loss ratio—direct costs divided by capitated revenue—was 81.0%, versus 85.5% in the second quarter and 67.8% a year earlier.
Starling Oncology (NASDAQ: STLN) will release its third quarter 2026 financial results on November 5, 2026, followed by a conference call. The call begins at 5:00 p.m. Eastern Time and will also be webcast through the company’s Investor Relations website. A telephone replay will be available approximately three hours after the call until November 19, 2026, at 11:59 p.m. Eastern Time.
Starling Oncology (NASDAQ: STLN) highlighted recent industry conference participation by its physician leaders and previewed upcoming appearances focused on community oncology.
Jeffrey Langsam participated in Deutsche Bank’s Healthcare Summit on September 17, 2026, and Yale D. Podnos joined the Patient-Centered Oncology Care Conference on September 25. Podnos will join panels on cancer care economics and clinical trial access at the AVBCC Summit on October 8, 2026. He will also present on integrating behavioral health into community oncology at the APG Fall Conference on November 19, 2026.
Starling Oncology (NASDAQ: STLN) announced that CEO Dr. Daniel Virnich and CFO Rob Carter will participate in the Wells Fargo Healthcare Conference in Boston on Tuesday, September 8, 2026. Their appearance will include a fireside chat scheduled from 4:30–5:05 p.m. ET, with a webcast available via the Investor Relations section of the company’s website.
Starling Oncology (NASDAQ: STLN) launched Starling Nexus, a proprietary technology platform designed to streamline oncology workflows by unifying clinical decision support, evidence-based pathways and prior authorization into a single digital system.
The platform aims to improve NCCN guideline compliance and reduce delays and errors linked to fragmented authorization processes. According to Starling Oncology, Starling Nexus connects utilization management with real-time decision support and will evolve into a hub integrating ancillary services such as pharmacy and clinical trials, supporting physicians, health plans and patients within its value-based cancer care model.
Starling Oncology (NASDAQ: STLN) reported second quarter 2026 revenue of $161.3 million, up 34.6% year over year, with gross profit rising 55.2% to $27.2 million. Net loss narrowed to $9.8 million, or $(0.08) per share, and Adjusted EBITDA turned positive at $0.2 million. Cash and cash equivalents reached $41.1 million at June 30, 2026.
According to the company, strong specialty pharmacy performance and growth in capitated lives supported results. Full-year 2026 guidance was raised to revenue of $650–$670 million and gross profit of $105–$110 million, with Adjusted EBITDA now expected at $2–$7 million. Starling also expects about $150 million in 2026 capitated revenue and projects its medical loss ratio at 80%–90% over the next twelve months.